ArticleDrug delivery and translational research2026
uPAR-targeted stealth small-sized mesoporous silica nanoparticles for pancreatic cancer therapy.
Article in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is characterized by a dense fibrotic stroma and aberrant tumor-associated vasculature, which impede nanoparticle (NP) penetration and accumulation, thereby reducing therapeutic efficacy. To overcome these barriers, small, selective NPs with prolonged circulation times are essential for effective tumor tissue penetration. In this study, mesoporous silica nanoparticles (MSNs) with a diameter of 45 nm were synthesized and coated with an albumin corona using a novel pH-sensitive "click" acetal linker. The albumin corona acts as a pH-responsive gatekeeper and scaffold, decorated with two distinct peptides: U11 and a CD47-derived "minimal peptide." The U11 peptide enables active targeting of PDAC cells, increasing NP uptake by 1.6- and 2.2-fold in MIA PaCa-2 and PANC-1 cells, respectively. The CD47-mimicry peptide promotes immune evasion, reducing macrophage uptake in RAW 264.7 cells by 2.3-fold compared to uncoated MSNs. The NPs were loaded with a camptothecin (CPT) gemcitabine (GEM) conjugate. The cytotoxicity of this pH-sensitive nanocarrier was evaluated in vitro against PANC-1 and MIA PaCa-2 pancreatic cancer cell lines.
Indexed as
Identifiers
42062704What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.